MGXHealthcareNano-Cap
Metagenomi Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Metagenomi Therapeutics, Inc. (MGX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are MGX insiders buying or selling?
Metagenomi Therapeutics, Inc. insiders reported 1 open-market buys ($13.0M) and 23 sells ($107.4K) across 24 Form 4 filings — a net buying position of $12.9M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jun 10, 2026)
Total Form 4 filings
24
SEC EDGAR
Insider filers
6
Insider buys (1)
$13.0M
Insider sells (23)
$107.4K
Insider sentiment
Net buyingNet insider flow of $12.9M in net buying.
Recent MGX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Pamela Wapnick | Chief Financial Officer | Sale | 2.9K | $1.30 | $3.7K |
| Jun 10, 2026 | Jian Irish | President and Chief Executive Officer | Sale | 3.7K | $1.30 | $4.9K |
| Jun 10, 2026 | Matthew Wein | Title: General Counsel, Compliance Officer and Corporate Secretary | Sale | 558 | $1.30 | $724.84 |
| Mar 9, 2026 | Pamela Wapnick | Chief Financial Officer | Sale | 1.6K | $1.60 | $2.5K |
| Mar 9, 2026 | Matthew Wein | Title: General Counsel, Compliance Officer and Corporate Secretary | Sale | 482 | $1.60 | $771.2 |
| Mar 9, 2026 | Jian Irish | Chief Executive Officer | Sale | 1.6K | $1.60 | $2.6K |
| Dec 8, 2025 | Brian C. Thomas | Director | Sale | 3.8K | $1.77 | $6.8K |
| Dec 8, 2025 | Matthew Wein | Title: General Counsel, Compliance Officer and Corporate Secretary | Sale | 199 | $1.77 | $352.61 |
| Dec 8, 2025 | Pamela Wapnick | Chief Financial Officer | Sale | 1.6K | $1.77 | $2.8K |
| Dec 8, 2025 | Jian Irish | Chief Executive Officer | Sale | 1.6K | $1.77 | $2.8K |
| Dec 2, 2025 | Brian C. Thomas | Director | Sale | 2.7K | $1.81 | $4.9K |
| Dec 2, 2025 | Pamela Wapnick | Chief Financial Officer | Sale | 1.6K | $1.81 | $2.9K |
| Dec 2, 2025 | Jian Irish | Chief Executive Officer | Sale | 1.6K | $1.81 | $2.9K |
| Dec 1, 2025 | Matthew Wein | Title: General Counsel, Compliance Officer and Corporate Secretary | Sale | 199 | $1.81 | $360.19 |
| Jun 9, 2025 | Matthew Wein | Title: Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary | Sale | 199 | $1.75 | $348.25 |
| Jun 9, 2025 | Sarah B. Noonberg | Chief Medical Officer | Sale | 5.2K | $1.75 | $9.2K |
| Jun 9, 2025 | Pamela Wapnick | Chief Financial Officer | Sale | 1.6K | $1.75 | $2.8K |
| Jun 9, 2025 | Brian C. Thomas | Chief Executive Officer | Sale | 10.8K | $1.75 | $18.9K |
| Jun 9, 2025 | Jian Irish | Title: President and Chief Operating Officer | Sale | 6.4K | $1.75 | $11.2K |
| Mar 7, 2025 | Matthew Wein | Title: Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary | Sale | 930 | $1.87 | $1.7K |
| Mar 7, 2025 | Pamela Wapnick | Chief Financial Officer | Sale | 1.8K | $1.87 | $3.4K |
| Dec 6, 2024 | Pamela Wapnick | Chief Financial Officer | Sale | 1.6K | $1.86 | $2.9K |
| Sep 6, 2024 | Pamela Wapnick | Chief Financial Officer | Sale | 6.3K | $2.88 | $18.0K |
| Feb 16, 2024 | Novo Holdings A/S | 10% Owner | Purchase | 900.0K | $14.47 | $13.0M |
Showing the 24 most recent of 24 Form 4 filings for Metagenomi Therapeutics, Inc..
Most active MGX insiders
- Pamela Wapnick8 filings
- Matthew Wein6 filings
- Jian Irish5 filings
- Brian C. Thomas3 filings
- Novo Holdings A/S1 filing
Ask anything about MGX insider activity
Use Trabud's AI agent to query Metagenomi Therapeutics, Inc.'s Form 4 history in plain English — "Show me MGX CEO purchases this year" or compare it against any other ticker.
Open the AI agentMGX insider trading FAQ
Are Metagenomi Therapeutics, Inc. insiders buying or selling?
Across 24 SEC Form 4 filings, Metagenomi Therapeutics, Inc. (MGX) insiders reported 1 open-market purchases totaling $13.0M and 23 sales totaling $107.4K. That is a net buying position of $12.9M.
How many insiders trade MGX stock?
6 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Metagenomi Therapeutics, Inc.. The most recent filing was accepted on Jun 10, 2026.
Where does Trabud get MGX insider trading data?
All MGX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.